How AI is speeding up COVID-19 diagnosis

Healthcare organizations are still dealing with COVID-19 patients, and testing applications are ramping up all over the U.S. At the same time, AI is stepping in to help speed up the diagnosis of COVID-19 and expedite how much time healthcare professionals spend determining COVID-19 pneumonia and non-COVID-19 cases.

The AI tool is developed by researchers from Simon Fraser University and Providence Health Care and is currently in the validation phase at St. Paul’s Hospital in Vancouver, Canada. It works by analyzing a patient’s chest x-ray image, using bio-image detection to determine if a positive pneumonia case is consistent with COVID-19. Researchers used x-ray images of COVID-19 and non-COVID-19 to refine the machine learning system and find the unique characteristics of the virus.

It is not a standalone diagnosis tool, but it can help doctors and professionals quickly assist confirmation of their suspicions about a patient’s diagnosis. The tool can be used with others, such as CT scans.

“Instead of doctors checking each X-ray image individually, this system is trained to use algorithms and data to identify it for them,” Yagiz Aksoy, assistant professor in the School of Computing Science’s GrUVi Lab, said in a statement.

The tool can also detect and classify other types of chest x-ray pneumonia images, including bacterial, fungal and other viral cases.

Upon approval, the organizations plan to make the tool available for free, with support from the U.N. The United Nations Global Platform already holds a beta version of the tool and “is whitelisted in the [Amazon Web Services] Machine Learning Marketplace,” according to a press release.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.